

Review Article

Antifungal Compounds against *Candida* Infections from Traditional Chinese Medicine

Xin Liu,¹ Zhiming Ma,² Jingxiao Zhang,³ and Longfei Yang⁴

¹Eye Center, The Second Hospital of Jilin University, Changchun 130041, China

²Department of Gastrointestinal Nutrition and Hernia Surgery, The Second Hospital of Jilin University, Changchun 130041, China

³Department of Emergency, The Second Hospital of Jilin University, Changchun 130041, China

⁴Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun 130041, China

Correspondence should be addressed to Longfei Yang; yanglongfei@jlu.edu.cn

Received 25 August 2017; Revised 25 November 2017; Accepted 6 December 2017; Published 28 December 2017

Academic Editor: Nikos Chorianopoulos

Copyright © 2017 Xin Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infections caused by *Candida albicans*, often refractory and with high morbidity and mortality, cause a heavy burden on the public health while the current antifungal drugs are limited and are associated with toxicity and resistance. Many plant-derived molecules including compounds isolated from traditional Chinese medicine (TCM) are reported to have antifungal activity through different targets such as cell membrane, cell wall, mitochondria, and virulence factors. Here, we review the recent progress in the anti-*Candida* compounds from TCM, as well as their antifungal mechanisms. Considering the diverse targets and structures, compounds from TCM might be a potential library for antifungal drug development.

1. Introduction

One severe health threat is infections caused by fungal pathogens, among which *Candida* species are the second most common fungal pathogen next to *Cryptococcus neoformans*, responsible for about 400,000 life-threatening infections per annum in the worldwide with a mortality as high as 40% [1, 2]. *Candida* spp. accounted for 98% of central venous catheter-related fungemias in patients with cancer [3]. Among the many *Candida* species, *Candida albicans* is the most common fungal pathogen of human diseases, followed by *Candida glabrata*, *Candida parapsilosis*, *Candida tropicalis*, and *Candida krusei* [2].

As the major opportunistic fungal pathogen, *C. albicans* dwells on the skin, in the oral cavity, mucosa of gut, and urogenital tract as a symbiotic fungus under normal conditions [4]. The host could discern the commensal and pathogenic state of *C. albicans*, rendering this fungus under the surveillance of immune system, and the bacterial microbe of locales where *C. albicans* colonize also contributes to keeping this fungus in check [5, 6]. The host defense against *C. albicans* relies on a complicated network consisting of

innate and adaptive immune components (e.g., epithelial cells, macrophages, neutrophils, dendritic cells, defensins, and complement). When the hosts encounter lower functions of immune system (resulting from HIV infection, organ transplant, and cancer treatment [7]) or disequilibrium of microflora due to the use of antibiotics [8], mucocutaneous and superficial infections, such as oral thrush and vaginitis, come up. This fungal pathogen could also cause life-threatening systematic infections such as candidemia. Other predisposing factors of *Candida* infections include diabetes and old age [9]. Among the nosocomial bloodstream infections, infections caused by *C. albicans* are the fourth prevalent [10].

In present, the therapeutic drugs for *Candida* infections are limited to five classes of compounds: polyenes, allylamines, azoles, fluoropyrimidines, and echinocandins [11], and amphotericin B, terbinafine, fluconazole, 5-fluorocytosine, and caspofungin are examples for them [12]. Drug resistance emerges due to pervasive application of antifungal drugs, such as fluconazole and voriconazole, for both prophylactic and therapeutic purposes [13]. Cellular and molecular

mechanisms underlying drug resistance may include reduced accumulation of intracellular drugs because of increased drug efflux (such as elevated mRNA levels of members of ABC transporter superfamily), mutations in genes of target protein (resulting in elevated levels of target protein or reduced affinity to targets), and modification of metabolism pathways (such as altered synthetic pathway of sterol which plays an important role in both structure and function of fungal cell wall) [14]. Researches indicate extensive regulation of intracellular processes in response to antifungal drugs. The fungistatic property of some drugs such as azoles and 5-flucytosine also contributes to the emergence of resistance [10], while the formation of biofilm may contribute to and elevate the resistance [15]. The paucity of antifungal drugs and the emergence of resistance make it a pressing mission to discover and identify new hits and leads from synthesized chemicals or natural products. Compared to synthesized chemicals, natural products have many advantages such as structural diversity and relatively low toxicity.

Natural products provide a potential source for antifungal drugs, either in their nascent form or as original templates for structure-optimizing for more effective and safe derivatives [16, 17]. Among the marketed antibiotics used clinically, about 80% are derived from natural products [17]. Traditional Chinese medicine is composed of mainly herbs that have been used for thousands of years. Recently, single compounds isolated from many traditional Chinese herbs have been demonstrated to have various kinds of pharmacological activities, such as antibacterial, antitumor, antiviral, and antifungal activities. Considering the present lack of antifungal drugs and the usefulness of traditional Chinese medicine, it may be a promising strategy to develop antifungal agents from traditional Chinese medicines. Here, recent antifungal compounds from traditional Chinese medicines will be briefly reviewed.

2. Compounds Targeting Cell Membrane

The plasma membrane keeps the cytoplasm from circumambient environment. The integrity and fluidity of cell membrane means being important to the survival and growth of fungal cells; one important reason is that many enzymes, channels, and transporters of drugs lie on the cell membrane. Cell membrane is the location where many metabolic processes occur and meanwhile it provides a barrier to environmental stresses.

Derived from *Sambucus williamsii*, a traditional herb broadly used for hundreds of years to treat fractures, edema, and scratches in East Asian countries, (-)-olivil-9'-O- β -D-glucopyranoside exerts its antifungal activity against *C. albicans* by depolarizing the cell membrane evidenced by influx of propidium iodide (PI) and elevated fluorescence of 3,3'-dipropylthiacarbocyanine iodide (DiSC₃(5), a cyanine dye for measuring membrane potential) [18]. More important and encouraging is that this compound shows little hemolytic activity on human erythrocytes [18]. Two other components (both are lignans) from the same plant, lariciresinol [19] and (+)-pinoresinol, show similar anti-*Candida* effects by

damaging the plasma membrane leading to permeabilization [19, 20]. The differential effects upon human and fungi cells imply that it may act on unique components of fungi cells, which needs further identification. Another compound isolated from *Sambucus williamsii*, glochidioboside, shows antifungal activity similar to that of (-)-olivil-9'-O- β -D-glucopyranoside against *C. albicans* by forming pores on cytoplasmic membrane with a radius range from 1.4 to 2.3 nm [21]. One of the products from the secondary metabolism of *Trachelospermum asiaticum*, dihydrodehydrodiconiferyl alcohol 9'-O- β -D-glucoside, could also depolarize the transmembrane potential via forming pores with radii ranging from 0.74 nm to 1.4 nm [22]. Changes in granularity and size revealed by the flow cytometry assays also involves alterations of the membrane properties such as osmolarity [22]. However, there are no evident causative link between disruption of membrane potential and changes of osmolarity and no conclusions about which comes first, which remain to be further investigated.

As a component of fungal cell membrane different from the mammalian parallel and a critical modulator for differentiation and pathogenicity of fungi, the glycosphingolipid glycosylceramide in the cell envelope maybe presents a better target for antifungal therapeutic treatments [23].

Ergosterol plays important roles in regulating the fluidity of the cell membrane and cell division of fungal cells, while the structural and conformational differences between ergosterol and sterol (the counterpart of ergosterol in mammalian cells) underlie the antifungal mechanism of the polyenes such as amphotericin B [12, 24]. Despite the low bioavailability and high toxicity of ergosterol-targeting drugs in humans [25, 26], ergosterol still presents a good target for antifungal drugs due to the importance of cell membrane.

Magnolol, one of the major pharmacologically active compounds from *Magnolia officinalis* which could be used to ameliorate the symptoms such as anxiety, asthma, nervous disturbance, and digestive problems [27], could reduce the content of ergosterol in the widely used *C. albicans* SC5314 [28]. Compounds from essential oil of mint, such as menthol, menthone, and carvone, suppress the growth of *C. albicans* through decreasing the contents of ergosterol in cell membrane and the hemolysis caused by them is less than that induced by fluconazole [29]. The ergosterol levels could also be decreased by carvacrol (isolated from *Origanum dictamnus* L.) and thymol, which could exert their influence on the antioxidant defense system, increase the membrane permeability, block the efflux pumps, and thus restore the antifungal susceptibility [30, 31]. Aside from *Candida* species, antifungal activities of this compound against other fungi such as *Monilinia laxa* have been identified [31-33].

Transporters such as ABC transporters on cell membrane could induce the efflux of antifungals, thus compromising the effects of drugs. Treatment with magnolol could significantly decrease the efflux of fluconazole, thus enhancing the antifungal effects of fluconazole [28].

PM-H⁺ ATPase on cell membrane plays a vital role in keeping the transmembrane electrochemical proton gradient which is important for the obtaining of nutrients. The intercellular pH hemostasis modulated by PM-H⁺ ATPase is

of great physiological importance. And the enzymatic activity of PM-H⁺ ATPase is positively correlated with cell viability [29]. Carvone, menthol, and menthone could suppress the PM-H⁺ ATPase activity, presumably the primary cause of the antifungal effects [29]. The results also indicated the existence of targets that could be easily touched by external drugs, despite the fact that more efforts need to be made.

3. Compounds Targeting Cell Wall Components

The structural integrity of cell wall is vital to the survival and growth of fungal cells, as it provides a shelter from osmotic pressure and other stresses in milieu. Recent studies showed that it likely plays an important role in the colonization and biofilm formation of *C. albicans*, as proteins associated with adhesion, such as Als1, Als3, and Hwp1, are cell wall proteins [34, 35]. Damaged cell wall leads to osmotic fragility of the fungal cell, disrupted membrane, efflux of cytoplasmic contents, and suppressed growth of fungi [13]. Cell wall is lacking in mammal cells, which makes it a preferential target for potential antifungal drugs for safety considerations. The cell wall of *Candida* species holds glycoproteins and abundant carbohydrates, among which are largely glucan, mannose, and chitin [10]. In the following part of this review we will discuss the plant-derived antifungal components acting on cell wall elements or on the synthesis of those elements.

3.1. Chitin. As one of the major components comprising fungal cell wall, chitin is a long linear homopolymer of β -1,4-linked *N*-acetylglucosamine (GlcNAc) and is synthesized by the incorporation of GlcNAc units from the precursor uridine 5'-diphospho-*N*-acetylglucosamine (UDP-GlcNAc) in a reaction catalyzed by chitin synthetase (CHS) [36, 37].

Despite the small percentage in the cell wall, chitin plays important roles in maintaining the mechanical strength of the fungal cell wall, thus keeping the integrity of the fungal cell wall [38]. Damage to the cell wall may be ameliorated by the elevated quantity of chitin in cell wall due to increased synthesis and/or decreased degradation of chitin, which may increase the tolerance to antifungal drugs [38]. Since this material does not exist in human cells, this presents an attractive target for antifungal therapies [36]. The chemical structures of the classic inhibitors of CHS, namely, polyoxins and nikkomycins, make themselves be degraded easily *in vivo* and difficult to go through the cell membrane, leading to a low antifungal activity [36, 39]. This prompts us to find new CHS inhibitors.

Plagiochin E derived from liverwort *Marchantia polymorpha* L. exerts its antifungal effect through inhibiting the expression of chitin synthetase gene 1 (CHS1) and therefore suppressing the activity of CHS and subsequent synthesis of chitin both *in vivo* and *in situ* [13]. Interestingly, the expression of CHS2 and CHS3 gene was upregulated by this macrocyclic compound [13]. However, the same group found that plagiochin E exposure of *C. albicans* could induce accumulation of reactive oxygen species (ROS) through malfunction of mitochondria, while pretreatment with L-cysteine could contribute to the survival of *C. albicans* [40].

These studies indicate that plagiochin E may exert its antifungal activity through diverse currently unknown mechanisms.

3.2. Glucan. This carbohydrate polymer, together with chitin, is the structural component which holds the integrity and physical strength of the cell wall. The production and assembly of glucan in *C. albicans* need a series of enzymes and regulatory networks, which are fungal-specific and thus render some fascinating targets for antifungal therapies [41]. The most famous drugs of this kind are echinocandins such as caspofungin and micafungin which inhibit the synthesis of β -1,3-glucan [10]. Although they are fast-acting, less toxic, and fungicidal [10], mutations in β -1,3-glucan synthase that confer resistance to caspofungin have already emerged. Recently, a novel terpene antifungal SCY-078 demonstrated fungicidal activity against *C. albicans* through inhibiting glucan synthase [42]. Sodium houuttuyfonate, a derivative from *Houuttuynia cordata* Thunb., might exert its synergistic effect with fluconazole through interfering with β -1,3-glucan synthesis and transportation [43].

4. Compounds Targeting Mitochondria

The classical respiratory chains of mitochondria are centers of energy production through oxidative phosphorylation, and meanwhile mitochondria are the organelles that produce metabolic intermediates used for amino acid and lipid biosynthesis. Both energy supply and metabolites are indispensable for the survival and growth of *C. albicans*, as well as major cellular event such as yeast-to-hyphal transition. Mitochondria are also involved in efflux-mediated resistance of *C. albicans* to fluconazole [44] while *in vitro* resistance of *C. glabrata* to azoles is associated with mitochondrial DNA deficiency [45]. Resistance to azole is also likely to be related with decreased generation of endogenous ROS that are harmful to DNA, proteins, and lipids while ROS are mainly generated by enzyme complexes (Complex I and Complex III) in classical respiratory chain as by-products of selective degradation of mitochondria [44]. Elevated levels of intracellular ROS are involved in the antifungal effects of fluconazole and miconazole and ROS also play an important role in intrinsic mitochondrial pathway of apoptosis in *C. albicans* [46, 47]. Besides the common enzymes in classical respiratory chain in *C. albicans* cells, there also exist rotenone-insensitive NAD(P)H dehydrogenase and alternative terminal oxidases constituting the cyanide-insensitive respiratory chain [48–50]. In addition, *C. albicans* and *C. parapsilosis* have additional respiratory pathway called parallel respiratory chain [51]. The differences between fungal and mammal mitochondrial enzymes also make developing drugs targeting these enzymes possible [52]. This is the case of some agrichemicals such as boscalid and carboxin that inhibit the succinate dehydrogenase in fungal cells [53]. Although there are only few studies on drugs targeting specifically mitochondria of *Candida* spp., ME1111 [2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol] did exert its antifungal effects upon human pathogens *Trichophyton mentagrophytes* and *Trichophyton rubrum* through inhibiting succinate dehydrogenase in mitochondria with high selectivity (the IC₅₀ values

for human cells are more than thirty times higher than that for fungal cells) [53]. In a word, mitochondria might be a promising target for antifungal therapies.

As an important constituent of many herbs of Berberidaceae family such as *Berberis vulgaris*, berberine exerts its antifungal action by induction of mitochondrial dysfunction and increased ROS generation, and its effects are in synergy with fluconazole, even in fluconazole-resistant clinical isolates [54–56]. Moreover, berberine treatment could also culminate in disruption of cell wall integrity in *C. albicans* [57] and inhibit the overexpression of drug resistance gene CDR1 induced by fluphenazine [58]. Although berberine could induce apoptosis in many human cells such as HL-60 leukemia cells and thyroid carcinoma cells [59, 60], berberine could recover the mitochondrial function induced by high-fat feeding in a rat model and could decrease the triglyceride accumulation in the liver in mice [61, 62]. It also markedly decreased the ROS generation in mitochondria [62]. This makes berberine a good candidate for antifungal development although there are much more to be done.

(+)-Medioresinol from the anti-inflammatory, analgesic, and diuretic herbal plant *Sambucus williamsii*, imposed on *C. albicans*, could induce generation of ROS and cell cycle arrest and finally apoptosis [47]. Although (+)-medioresinol could inhibit *in vitro* the proliferation of mammalian cells such as A549, SK-MEL-2, SK-OV-3, and HCT-15 cells at high concentrations, the IC₅₀ values for these cell lines were much higher than the MIC value against *C. albicans* cells [47, 63]. In a cohort study in Sweden, (+)-medioresinol in food did not clearly reduce the risk of esophageal and gastric cancers, but at least this compound in diet did not show bad effects [64, 65]. The safe profile of this lignin makes it more inspiring although there is no report on its effects on mammalian mitochondria.

Allyl alcohol from garlic (*Allium sativum*), which has been used as a traditional antimicrobial agent for thousands of years, exerts its antifungal effect through introducing oxidative stress such as increasing ROS production and depleting glutathione. The known targets of allyl alcohol are cytosolic alcohol dehydrogenases Adh1 and Adh2 and the mitochondrial Adh3 [66]. Although allyl alcohol could be released after ingestion of garlic, its toxicity, mediated by acrolein the production of which is catalyzed by alcohol dehydrogenase in rodents, prevents its development as antifungal agent [66, 67].

Baicalin could inhibit the activities of enzymes in mitochondria (such as Ca²⁺-Mg²⁺-ATPase, succinate dehydrogenase, and cytochrome oxidase) and induce cell cycle blockage and apoptosis in *C. albicans* cells [68]. However, in mammalian cells (e.g., CHO cell), baicalin could reduce ROS production [69]. There are also reports showing that baicalin induces apoptosis in human non-small lung cancer cells and osteosarcoma cells through ROS production [70, 71]. Baicalin could protect mitochondria from damage caused by streptozotocin and hepatic ischemia/reperfusion and increase the activity of citrate synthase in rats [72, 73]. Despite the discrepancy between the roles of baicalin in different cells in ROS production, the *in vivo* tests might support the use of baicalin as an antifungal candidate [69, 71, 73].

Shikonin, the major active compound isolated from *Lithospermum erythrorhizon*, could induce the endogenous ROS production, reduce the mitochondrial membrane potential, and alter mitochondrial aerobic aspiration [74]. In human gastric cancer cells and TT medullary thyroid carcinoma cells, shikonin could also induce ROS production and mitochondria-mediated apoptosis [75, 76]. The almost same cytotoxicity for fungal cells and mammalian cells makes shikonin a less attractive candidate for antifungal development.

Curcumin, the yellow pigment isolated from the turmeric (the rhizome of the plant *Curcuma longa* Linn) could also be used as an adjunct drug to treat pathogenic microorganisms such as *Helicobacter pylori*, methicillin-resistant *Staphylococcus aureus* (MRSA), and *Trypanosoma cruzi*. Antifungal activities against various kinds of fungi such as *Candida* species, *Cryptococcus neoformans*, *Aspergillus* spp., and *Sporothrix schenckii* have also been demonstrated by this compound [77, 78]. Curcumin could increase ROS production and apoptosis in *C. albicans* cells, either alone or in synergy with antifungal drugs such as azoles and polyenes [78, 79]. In mammalian cells, curcumin could protect mitochondria from damage and increase the biogenesis of mitochondria, although apoptosis-inducing effects of curcumin have also been reported in cancer cells [80, 81]. Most importantly, this compound could be safe with a maximum tolerance dose of 12,000 mg/day in Phase I clinical trials [82], which present an advantage over other antifungal compounds. However, the poor oral bioavailability and poor solubility in aqueous solutions impede its use and promote the development of methods for delivering curcumin to fight *Candida* infections [83].

Silibinin, the most famous and active compound isolated from *Silybum marianum* (milk thistle) traditionally used to protect from liver injury, could induce apoptosis related to mitochondrial Ca²⁺ influx in *C. albicans* cells [84, 85]. Silibinin could alleviate mitochondrial dysfunction in mice model of cisplatin-induced acute kidney injury through Sirt3 activation, although *in vitro* proapoptotic effects through inducing ROS production have been also reported [86, 87]. The safe profile with silibinin, evidenced by marketed health food and clinical trials, makes silibinin a very promising candidate for antifungal therapies against *Candida* infections although there is still a long way to go [88].

5. Virulence Factors

Virulence factors contributing to the *Candida* infections hold adhesins, virulence enzymes (secreted aspartyl proteinase and phospholipases functioning in host tissue invasion) [89], and morphological transition [90].

5.1. Yeast-to-Hypha Transition. Although both budding yeast type and hyphal type of *C. albicans* have been found at the loci of infections, the transition of yeast-to-hypha in *C. albicans* is considered to be a major factor involved in the colonization, invasion/penetration, virulence, immune evasion, and survival in the host tissues [91–93]. For instance, most of the hyphal growth of *C. albicans* could not be

suppressed by the macrophages after engulfment *in vitro* and lysis of macrophage caused by penetration of hypha was also observed [94]. What is worth mentioning is that, soon after phagocytosis by macrophages, the hyphal formation of *C. albicans* is required (but not sufficient) for inducing the proinflammatory pyroptosis, a kind of programmed cell death of macrophages mediated by inflammasome, before other macrophages are killed by the robust hyphal formation of *C. albicans* [95–97]. Although recently identified Candidalysin secreted by *C. albicans* hyphae plays a vital role in the mucosal pathogenesis through its cytolytic effects, no reports about the relationship between it and macrophages' damage have been published [98]. Nonetheless, Candidalysin renders a promising antifungal target for *C. albicans*. Moreover, hyphae could also support the complicated characteristic structures of mature biofilms which will be discussed later [99]. Induced by exogenous stressors (such as presence of serum and alterations in temperature, pH, levels of oxygen and glucose [91], the presence of *N*-acetyl-*D*-glucosamine (GlcNAc) [100], adherence, and starvation/nutrient limitation [92]), filamentation of *C. albicans* involves underlying alterations in protein synthesis and metabolic changes which are mainly the RAS1-Cyr1p-cAMP-PKA-EFG1 pathway and mitogen-activated protein kinase (MAPK) signaling [91, 92]. Both signaling pathways are governed by the membrane-integrated small GTPase Ras1 [101].

Magnolol and honokiol, two kinds of neolignan isolated from the root, stem, and branch bark of *Magnolia officinalis*, could inhibit the yeast-to-hypha transition of *C. albicans* under many culture conditions. Treatment of magnolol or honokiol could induce downregulation of components of the Ras1-cAMP-Efg1 pathway (such as RAS1, EFG1, TECL1, and CDC35 (the orthologue of Cyr1)), as well as reduced expression levels of the hypha-specific genes ECE1, HWP1, and ALS3, while exogenous cAMP could restore the filamentous growth in the presence of the drugs. These suggest that the transition-inhibiting effects of these two compounds may be associated with the suppression of Ras1-cAMP-EFG1 pathway [102]. Curcumin could also inhibit the yeast-to-hypha transition through targeting the transcriptional suppressor TUP1 (thymidine uptake 1) [79]. Licochalcone-A, a bioactive polyphenol from roots of licorice that has been used as a herbal remedy for hundreds of years, could inhibit the morphological transition [103]. The compound glabridin from licorice and the anthraquinone purpurin from madder root (*Rubia tinctorum* L.) could also inhibit the transition [104, 105].

Apart from the regulating role in antifungal resistance in planktonic *C. albicans*, the chaperone Hsp90 can also modulate the transition by inhibiting the filamentation via cAMP-PKA signaling [106]. Hsp90 deletion in *C. albicans* leads to virulent attenuation in a systemic candidiasis model [107]. So comes the hypothesis that inhibitors of Hsp90 may exhibit anti-*Candida* effects.

5.2. Biofilm Formation. Most infections caused by *Candida* spp. involve biofilms formed on the surfaces of biomaterials (such as intravascular catheters and prosthetic heart valves) and biotic mucosa (such as oral cavity and wound

surface) [108]. Biofilm, buried in the extracellular matrix (ECM), holds a complicated three-dimensional architecture consisting mainly of yeast form cells and hyphal cells with broad heterogeneity in space [15, 109]. The spatial, structural, and metabolic heterogeneity of biofilms is considered to promote influx of nutrients, efflux of waste products, and establishment of microniches, thus facilitating the adaption of biofilms to the hypoxic environment [99, 110]. Beginning with the adherence of fungal cells to the substrate surface, the development of biofilm undergoes proliferation, maturation, and finally dissemination to finish a cycle and the cycle could repeat itself to expand the fungal population [15]. Cells in the biofilm exhibit great advantages over their free-living parallels in surviving such as increased resistance to many antimycotic drugs (e.g., *C. albicans* cells of biofilm are almost 1000 times resistant to fluconazole than free-living cells [111]) and protection offered by ECM [15]. The elevated resistance to antimycotic drugs and the ability to withstand host immune defenses, as well as the role as a reservoir for continuing infections, of *Candida* biofilms cause important clinical consequence and the presence of biofilms increases the morbidity and mortality of *C. albicans* relative to strains that could not form biofilms [99, 112]. Therefore, biofilm formation is considered as a potent virulence factor [34]. Now the *Candida* biofilms attract more and more attention, which could be reflected by the increasing number of publications on *Candida* biofilms.

Heat shock proteins play key roles in protecting cells from damage and repairing damage caused by insults, as well as in the protein synthesis, folding, transport and membrane translocation, and so on [9]. Compromising the function of Hsp90 in *C. albicans* by genetic manipulation or pharmacological means could reduce the dispersal and maturation of biofilms as well as increase the sensitivity to drugs used to abolish biofilms [106]. So inhibitors of Hsp90 may present a useful paradigm for therapy of infections caused by biofilm.

In *Candida* cells of biofilms, increased expression of many genes has been found such as genes involved in protein synthesis, drug transporting, adherence to matrix, and primary metabolism [109]. Genes encoding envelope proteins such as Hwp1, Als1, Als3, and Sun41 play critical roles in biofilm formation [92].

Although the structures of *C. albicans* biofilm can be disrupted by physical means such as mechanical removal by brushing on the surface of teeth and ultrasound (or sonication) treatment of implants [113], the clearance of *C. albicans* is primarily dependent on drugs which could prevent the formation of biofilm or abolish the matured biofilm.

Biofilm formation of *Candida* spp. and other fungi could be replicated in 96-well microtiter plates [36] as well as in animal paradigms [15], which provide us with useful tools to screen potential antifungal hits. Derived from *Cinnamomum zeylanicum*, cinnamon oil exhibits antifungal activity against *C. orthopsilosis* and *C. parapsilosis* through inhibiting the formation of biofilm as well as the growth of planktonic counterparts [114], although the exact mechanism is unknown. One of the major components cinnamaldehyde (of the oil) could also inhibit the biofilm formation of clinical isolates of *C. albicans* [115], and moreover it could suppress the

growth of *Aspergillus flavus* and *Aspergillus oryzae* which are culprits of food spoilage [116]. Berberine, an alkaloid from the medicinal plants such as *Coptis chinensis* and *Hydrastis canadensis*, also has antifungal activities against *C. albicans* biofilms, both alone and in synergy with miconazole [117]. Licochalcone-A also demonstrated *in vitro* and *in vivo* antifungal activity against *C. albicans* biofilms [103]. Purpurin also demonstrated antifungal activity against the formation and preformed biofilms of *C. albicans*, in addition to its capability of inhibiting morphological transition [104].

Aside from inhibiting the yeast-to-hypha transition, magnolol and honokiol also inhibit biofilm formation via suppressing adhesion and growth of *C. albicans* as is evidenced by XTT assay and confocal laser scanning microscopy. These two compounds could reduce the fungal burden and prolong the lifespan of *Caenorhabditis elegans* in a nematodes infection model [102]. What is more important, compounds at the concentrations used exhibit no adverse effect on the mammalian HSC-T6 cells and nematodes [102]. Curcumin could also inhibit the biofilm formation of *C. albicans* [118]. Thymol (5-methyl-2-(1-methylethyl) phenol), a major essential oil in the herb thyme (*Thymus vulgaris* L., Lamiaceae) which could be applied for treating multiple symptoms including bronchitis, whooping cough, and catarrh of the upper respiratory tract [119, 120], exhibits antifungal activity against fluconazole-sensitive and fluconazole-resistant isolates of *C. albicans* [121]. Recent study identified that thymol could inhibit the biofilm formation and development, and moreover this compound could enhance the host antimicrobial responses against *C. albicans* and increase the lifespan of *C. elegans* during the fungal infection [115, 122]. In addition, thymol has shown synergy with fluconazole against biofilms [115, 123]. Baicalein and aucubin from *Plantago major* (greater Plantain), a perennial herb used for wound healing, analgesic, anti-inflammatory, antioxidant, and infections, could inhibit the biofilm formation and decrease the cell surface hydrophobicity of *C. albicans* [124]. Eugenol, the major components of essential oils from *Syzygium aromaticum* (clove), possesses the capacity to inhibit the biofilm formation and preformed biofilms, more effective than marketed antifungal drug fluconazole. This compound could also produce synergistic effects with fluconazole [115, 123] and what is more, the structure-activity relationship of this compound is analyzed [125]. Another phenylpropanoid from clove, methyleugenol, also exhibits antifungal effect against fluconazole-resistant *Candida* isolates and synergistic effect with fluconazole [126]. Antibiofilm activity of menthol from mint, either alone or in combination with fluconazole, was also identified [123, 127]. So is the case with geraniol (3,7-dimethylocta-*trans*-2,6-dien-1-ol) [115], an acyclic monoterpene alcohol which could be isolated from many herbs such as *Pelargonium graveolens* (Geraniaceae), nutmeg, and ginger [128, 129]. Another compound from *Pelargonium graveolens*, linalool, also exhibits antifungal effect on the planktonic and biofilm cells of *C. tropicalis* [129]. Carvacrol could also sensitize the *Candida* biofilms, as well as the planktonic cells, to fluconazole [130]. Usnic acid (2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-1,3(2H, 9bH)-dibenzo-furandione), the major active component isolated from medicinal lichens such

as *Cladonia* and *Usnea* [131], could inhibit the formation of *Candida* biofilms and other virulent traits [132, 133]. Berberine, from *Berberis aquifolium*, *Hydrastis canadensis*, *Phellodendron amurense*, has the antifungal activities against fluconazole-resistant *Candida* spp. in planktonic and biofilm form [134]. Emodin from rhizomes of *Rheum palmatum* could inhibit the formation of biofilms and hyphal development of *C. albicans* [135].

5.3. Other Factors. Virulence in mice caused by *C. albicans* mutants deficient in isocitrate lyase I (ICLI, a major component of the glyoxylate cycle) is evidently less than the wide type equivalents, which indicates the involvement of the glyoxylate cycle in the pathogenesis of candidiasis [136]. ICLI, as well as malate synthase, is the distinctive enzyme that has not been observed in mammalian cells; thus it may render a unique target for inhibiting the virulence of *C. albicans* to combat this fungal pathogen. Recently, inhibitors of malate synthase demonstrated antifungal effect against *Paracoccidioides species* [137], while apigenin, the active flavone compound in Chinese herbs such as thyme, could inhibit the enzymatic activity of ICLI in *C. albicans* [138, 139]. Rosmarinic acid, the bioactive polyphenol in herbs such as basil (*Ocimum basilicum*), oregano (*Origanum vulgare*), sage (*Salvia officinalis*), and *Melissa officinalis*, has also been identified as an inhibitor of ICLI in *C. albicans* [138, 140]. Recent study by Ansari et al. demonstrated that both the enzymatic activity and mRNA expression of ICLI and malate synthase of *C. albicans* could be inhibited by the monoterpene perillyl alcohol, the active compound from edible and medicinal plant *Perilla frutescens* L. ex B. D. Jacks. (Lamiaceae) which has been used for treating colds, food allergy, and depression [141, 142]. Considering the absence of ICLI in human, the well-tolerated profile in human, and the fact that Phase II trials have been conducted in patients with cancers, perillyl alcohol might serve as an interesting candidate for antifungal therapies against *C. albicans* [143, 144].

Similar to *Pseudomonas aeruginosa*, communication among fungal cells is often associated with virulence [145]. Quorum sensing means that molecules secreted by the *C. albicans* cells in response to cell density could affect the behaviors of the cells. The formation of biofilms, hyphal growth, and virulence factors of *C. albicans* could also be regulated by quorum sensing [146]. The most famous quorum sensing molecule of *C. albicans* is farnesol, one autoregulatory sesquiterpene alcohol that could prevent the filamentation (through repressing the Ras1-cAMP-PKA signaling pathway [147]), shrink the biofilm (if added before attachment or after formation but not during the initial stages of biofilm growth [148]), and block other virulence factors [149]. So comes the strategy that targeting quorum sensing molecules may contribute to the antifungal therapies [146]. Indeed, the dietary flavonoid quercetin isolated from edible and medicinal lichen *Usnea longissimi* could sensitize fluconazole-resistant isolate NBC099 to fluconazole and this kind of sensitization could be the quercetin-induced production of farnesol [146].

Another quorum sensing molecule produced by *C. albicans*, tyrosol, could also affect the development of *Candida*

biofilms [150]. This aromatic alcohol could induce the morphological transition from yeast to hyphae. At high concentrations (above 200 mM), tyrosol could cause reduction in biofilms formed by *Candida* species as well as those by *Streptococcus mutans* [151].

Extracellular hydrolytic enzymes produced by *C. albicans* are considered as virulence factors liable for the penetration into and damage to host cells caused by this pathogenic fungus [152]. These enzymes include secreted aspartic proteinases, lipases, and hemolysins [34]. Quercetin could inhibit the activities of proteinase, esterase, phospholipase, and hemolysins of fluconazole-resistant *C. albicans* strain NBC099 [146]. In addition, this compound could also synergize with fluconazole against biofilm both *in vivo* and *in vitro* [153].

6. Compounds without Identified Mechanism

Anofinic acid and fomannoxin acid isolated from *Gentiana Algida* showed weak antifungal activities against *C. albicans*, while the esterification by introducing methyl group into those compounds could enhance the anti-*Candida* activities but decrease the activities against the *Cladosporium cucumerinum*, which is a kind of plant pathogenic fungus [154]. However, no further research about the antifungal mechanism has been performed since that finding. Anofinic acid could also be isolated from another traditional Chinese medicine, *Gentiana macrophylla*, which has been used for long as therapies for constipation, pains, jaundice, and rheumatism [155]. Another dihydroflavone isolated from *Gentiana macrophylla*, kurarinone, could also inhibit the growth of *C. albicans* [155]. Nyasol ((Z)-1,3-bis(4-hydroxyphenyl)-1,4-pentadiene), isolated from the herbal plant *Anemarrhena asphodeloides Bunge* (Liliaceae) which has been used in Chinese traditional medicine as antipyretic, anti-inflammatory, antidiabetic, and antidepressant agent [156], exhibits antifungal activity against *C. albicans* alone or in synergy with azoles [157, 158]. This compound also has activity against other fungal pathogens such as *A. flavus*, *Fusarium oxysporum*, *Pythium ultimum*, and *Rhizoctonia solani*, to name a few [158, 159]. Another compound from clove, isoeugenol, also exhibited antifungal activities against *C. albicans*, as well as *Aspergillus niger* [125]. α -Terpineol (2-(4-methyl-1-cyclohex-3-enyl) propan-2-ol), from *Artemisia annua*, could inhibit a series of *Candida* species isolated from denture stomatitis patients [160]. The sesquiterpene lactone isolated from *Inula racemosa* showed good antifungal activity against *Candida* species, as well as other human fungal pathogens such as *A. flavus* and *Geotrichum candidum* [161].

7. Conclusion

In summary, many natural compounds from TCM could exert their anti-*Candida* activities through different mechanism, providing a big reservoir for developing antifungal therapies.

Combination therapies are capable of increasing the efficacy and preventing the emergence of drug resistance and many approaches have been adopted to identify effective

combinations, especially the synergistic effects with marketed drugs [162–164]. An important part of the adjuvants to antibiotics might come from the previously undervalued part of chemical entities, which have been recently termed as dark chemical matter (DCM) [165]. Because these DCM showed little or no bioactivity in previous researches towards human targets, it may represent a novel and valuable repertoire for identifying hits and optimizing leads [165]. The machine learning-based synergism prediction may be a promising method to identify synergistic effects of marketed antifungal drugs and natural products isolated from traditional Chinese medicine [162]. Considering new proteins or biological processes that might be used as emerging targets such as histone deacetylase and ion homeostasis, compounds from TCM might play increasing important and diverse roles in developing antifungal therapies against *C. albicans*.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

References

- [1] G. D. Brown, D. W. Denning, N. A. R. Gow, S. M. Levitz, M. G. Netea, and T. C. White, "Hidden killers: human fungal infections," *Science Translational Medicine*, vol. 4, no. 165, Article ID 165rv13, 2012.
- [2] S. Giri and A. J. Kindo, "A review of *Candida* species causing blood stream infection," *Indian Journal of Medical Microbiology*, vol. 30, no. 3, pp. 270–278, 2012.
- [3] J. A. Lecciones, J. W. Lee, E. E. Navarro et al., "Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes," *Clinical Infectious Diseases*, vol. 14, no. 4, pp. 875–883, 1992.
- [4] J. Berman, "Candida albicans," *Current Biology*, vol. 22, no. 16, pp. R620–R622, 2012.
- [5] M. G. Netea, L. A. B. Joosten, J. W. M. Van Der Meer, B.-J. Kullberg, and F. L. Van De Veerdonk, "Immune defence against *Candida* fungal infections," *Nature Reviews Immunology*, vol. 15, no. 10, pp. 630–642, 2015.
- [6] A. da Silva Dantas, K. K. Lee, I. Raziunaite et al., "Cell biology of *Candida albicans*–host interactions," *Current Opinion in Microbiology*, vol. 34, pp. 111–118, 2016.
- [7] M. Richardson and C. Lass-Flörl, "Changing epidemiology of systemic fungal infections," *Clinical Microbiology and Infection*, vol. 14, no. 4, pp. 5–24, 2008.
- [8] B. J. Kullberg and M. C. Arendrup, "Invasive candidiasis," *The New England Journal of Medicine*, vol. 373, no. 15, pp. 1445–1456, 2015.
- [9] Y.-Y. Cao, Y.-B. Cao, Z. Xu et al., "cDNA microarray analysis of differential gene expression in *Candida albicans* biofilm exposed to farnesol," *Antimicrobial Agents and Chemotherapy*, vol. 49, no. 2, pp. 584–589, 2005.
- [10] S. S. W. Wong, L. P. Samaranyake, and C. J. Seneviratne, "In pursuit of the ideal antifungal agent for *Candida* infections: high-throughput screening of small molecules," *Drug Discovery Therapy*, vol. 19, no. 11, pp. 1721–1730, 2014.
- [11] A. Rabes, S. Zimmermann, K. Reppe et al., "The C-type lectin receptor mInCLE binds to streptococcus pneumoniae but

- plays a limited role in the anti-pneumococcal innate immune response," *PLoS ONE*, vol. 10, no. 2, Article ID 0117022, 2015.
- [12] F. C. Odds, A. J. P. Brown, and N. A. R. Gow, "Antifungal agents: Mechanisms of action," *Trends in Microbiology*, vol. 11, no. 6, pp. 272–279, 2003.
- [13] T. Sultan and S. A. Ali, "Psoralea corylifolia extracts stimulate cholinergic-like psoralen receptors of tadpole-tail melanophores, leading to skin darkening," *Journal of Receptors and Signal Transduction*, vol. 31, no. 1, pp. 39–44, 2011.
- [14] C. Limper, Y. Wang, S. Ruhl et al., "Compounds isolated from *Psoralea corylifolia* seeds inhibit protein kinase activity and induce apoptotic cell death in mammalian cells," *Journal of Pharmacy and Pharmacology*, vol. 65, no. 9, pp. 1393–1408, 2013.
- [15] C. G. Pierce, A. Srinivasan, P. Uppuluri, A. K. Ramasubramanian, and J. L. López-Ribot, "Antifungal therapy with an emphasis on biofilms," *Current Opinion in Pharmacology*, vol. 13, no. 5, pp. 726–730, 2013.
- [16] M. G. Moloney, "Natural products as a source for novel antibiotics," *Trends in Pharmacological Sciences*, vol. 37, no. 8, pp. 689–701, 2016.
- [17] T. Roemer, D. Xu, S. B. Singh et al., "Confronting the challenges of natural product-based antifungal discovery," *Chemistry & Biology*, vol. 18, no. 2, pp. 148–164, 2011.
- [18] M. A. Peralta, M. A. Da Silva, M. G. Ortega, J. L. Cabrera, and M. G. Paraje, "Antifungal activity of a prenylated flavonoid from *Dalea elegans* against *Candida albicans* biofilms," *Phytomedicine*, vol. 22, no. 11, pp. 975–980, 2015.
- [19] B. Hwang, J. Cho, I.-S. Hwang, H.-G. Jin, E.-R. Woo, and D. G. Lee, "Antifungal activity of lariciresinol derived from *Sambucus williamsii* and their membrane-active mechanisms in *Candida albicans*," *Biochemical and Biophysical Research Communications*, vol. 410, no. 3, pp. 489–493, 2011.
- [20] B. Hwang, J. Lee, Q.-H. Liu, E.-R. Woo, and D. G. Lee, "Antifungal effect of (+)-pinoresinol isolated from *Sambucus williamsii*," *Molecules*, vol. 15, no. 5, pp. 3507–3516, 2010.
- [21] H. Lee, H. Choi, H. J. Ko, E.-R. Woo, and D. G. Lee, "Antifungal effect and mode of action of glochidioboside against *Candida albicans* membranes," *Biochemical and Biophysical Research Communications*, vol. 444, no. 1, pp. 30–35, 2014.
- [22] H. Choi, J. Cho, Q. Jin, E.-R. Woo, and D. G. Lee, "Antifungal property of dihydrodehydrodiconiferyl alcohol 9*l*-O- β -D-glucoside and its pore-forming action in plasma membrane of *Candida albicans*," *Biochimica et Biophysica Acta (BBA) - Biomembranes*, vol. 1818, no. 7, pp. 1648–1655, 2012.
- [23] K. Kodar, S. Eising, A. A. Khan et al., "The uptake of trehalose glycolipids by macrophages is independent of mincle," *ChemBioChem*, vol. 16, no. 4, pp. 683–693, 2015.
- [24] J. B. Anderson, "Evolution of antifungal-drug resistance: mechanisms and pathogen fitness," *Nature Reviews Microbiology*, vol. 3, no. 7, pp. 547–556, 2005.
- [25] S. A. Ahmed and M. M. V. Baig, "Biotic elicitor enhanced production of psoralen in suspension cultures of *Psoralea corylifolia* L.," *Saudi Journal of Biological Sciences*, vol. 21, no. 5, pp. 499–504, 2014.
- [26] L. Ostrosky-Zeichner, A. Casadevall, J. N. Galgiani, F. C. Odds, and J. H. Rex, "An insight into the antifungal pipeline: selected new molecules and beyond," *Nature Reviews Drug Discovery*, vol. 9, no. 9, pp. 719–727, 2010.
- [27] N. Konstantinidou and J. P. Morrissey, "Co-occurrence of filamentation defects and impaired biofilms in *Candida albicans* protein kinase mutants," *FEMS Yeast Research*, vol. 15, no. 8, Article ID fov092, 2015.
- [28] L.-M. Sun, K. Liao, S. Liang, P.-H. Yu, and D.-Y. Wang, "Synergistic activity of magnolol with azoles and its possible antifungal mechanism against *Candida albicans*," *Journal of Applied Microbiology*, vol. 118, no. 4, pp. 826–838, 2015.
- [29] N. Samber, A. Khan, A. Varma, and N. Manzoor, "Synergistic anti-candidal activity and mode of action of *Mentha piperita* essential oil and its major components," *Pharmaceutical Biology*, vol. 53, no. 10, pp. 1496–1504, 2015.
- [30] A. Khan, A. Ahmad, L. Ahmad Khan, C. J. Padoa, S. van Vuuren, and N. Manzoor, "Effect of two monoterpene phenols on antioxidant defense system in *Candida albicans*," *Microbial Pathogenesis*, vol. 80, pp. 50–56, 2015.
- [31] H. S. Elshafie, E. Mancini, S. Sakr et al., "Antifungal activity of some constituents of *origanum vulgare* L. essential oil against postharvest disease of peach fruit," *Journal of Medicinal Food*, vol. 18, no. 8, pp. 929–934, 2015.
- [32] C. Marcos-Arias, E. Eraso, L. Madariaga, and G. Quindós, "In vitro activities of natural products against oral *Candida* isolates from denture wearers," *BMC Complementary and Alternative Medicine*, vol. 11, article 119, 7 pages, 2011.
- [33] A. Aznar, P. S. Fernández, P. M. Periago, and A. Palop, "Antimicrobial activity of nisin, thymol, carvacrol and cymene against growth of *Candida lusitanae*," *Food Science and Technology International*, vol. 21, no. 1, pp. 72–79, 2015.
- [34] D. Araújo, M. Henriques, and S. Silva, "Portrait of candida species biofilm regulatory network genes," *Trends in Microbiology*, vol. 25, no. 1, pp. 62–75, 2017.
- [35] M. Henriques, J. Azeredo, and R. Oliveira, "Candida species adhesion to oral epithelium: factors involved and experimental methodology used," *Critical Reviews in Microbiology*, vol. 32, no. 4, pp. 217–226, 2006.
- [36] K. De Cremer, I. Staes, N. Delattin, B. P. A. Cammue, K. Thevissen, and K. De Brucker, "Combinatorial drug approaches to tackle *Candida albicans* biofilms," *Expert Review of Anti-Infective Therapy*, vol. 13, no. 8, pp. 973–984, 2015.
- [37] F. Freire, P. P. de Barros, D. da Silva Ávila, G. N. B. Brito, J. C. Junqueira, and A. O. C. Jorge, "Evaluation of gene expression SAP5, LIP9, and PLB2 of *Candida albicans* biofilms after photodynamic inactivation," *Lasers in Medical Science*, vol. 30, no. 5, pp. 1511–1518, 2015.
- [38] L. P. Rosa, F. C. da Silva, M. S. Viana, and G. A. Meira, "In vitro effectiveness of 455-nm blue LED to reduce the load of *Staphylococcus aureus* and *Candida albicans* biofilms in compact bone tissue," *Lasers in Medical Science*, vol. 31, no. 1, pp. 27–32, 2016.
- [39] F. Shirazi and D. P. Kontoyiannis, "Micafungin triggers caspase-dependent apoptosis in *Candida albicans* and *Candida parapsilosis* biofilms, including caspofungin non-susceptible isolates," *Virulence*, vol. 6, no. 4, pp. 385–394, 2015.
- [40] S.-H. Lim, T.-Y. Ha, J. Ahn, and S. Kim, "Estrogenic activities of *Psoralea corylifolia* L. seed extracts and main constituents," *Phytomedicine*, vol. 18, no. 5, pp. 425–430, 2011.
- [41] L. E. O'Donnell, E. Millhouse, L. Sherry et al., "Polymicrobial *Candida* biofilms: friends and foe in the oral cavity," *FEMS Yeast Research*, vol. 15, no. 7, 2015.
- [42] B. Scorneaux, D. Angulo, K. Borroto-Esoda, M. Ghannoum, M. Peel, and S. Wring, "SCY-078 is fungicidal against *Candida* species in time-kill studies," *Antimicrobial Agents and Chemotherapy*, vol. 61, no. 3, Article ID e01961, 2017.
- [43] J. Shao, Y. Cui, M. Zhang, T. Wang, D. Wu, and C. Wang, "Synergistic in vitro activity of sodium houttuynonate with

- fluconazole against clinical *Candida albicans* strains under planktonic growing conditions," *Pharmaceutical Biology*, vol. 55, no. 1, pp. 355–359, 2017.
- [44] H. Guo, S. M. Xie, S. X. Li, Y. J. Song, X. Y. Zhong, and H. Zhang, "Involvement of mitochondrial aerobic respiratory activity in efflux-mediated resistance of *C. albicans* to fluconazole," *Journal de Mycologie Médicale*, vol. 27, pp. 339–344, 2017.
- [45] A. Defontaine, J.-P. Bouchara, P. Declerk, C. Planchenault, D. Chabasse, and J.-N. Hallet, "In-vitro resistance to azoles associated with mitochondrial DNA deficiency in *Candida glabrata*," *Journal of Medical Microbiology*, vol. 48, no. 7, pp. 663–670, 1999.
- [46] D. Kobayashi, K. Kondo, N. Uehara et al., "Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect," *Antimicrobial Agents and Chemotherapy*, vol. 46, no. 10, pp. 3113–3117, 2002.
- [47] J. H. Hwang, I.-S. Hwang, Q.-H. Liu, E.-R. Woo, and D. G. Lee, "(+)-Medioresinol leads to intracellular ROS accumulation and mitochondria-mediated apoptotic cell death in *Candida albicans*," *Biochimie*, vol. 94, no. 8, pp. 1784–1793, 2012.
- [48] R. Alonso-Monge, S. Carvahlo, C. Nombela, E. Rial, and J. Pla, "The Hog1 MAP kinase controls respiratory metabolism in the fungal pathogen *Candida albicans*," *Microbiology*, vol. 155, no. 2, pp. 413–423, 2009.
- [49] W.-K. Huh and S.-O. Kang, "Molecular cloning and functional expression of alternative oxidase from *Candida albicans*," *Journal of Bacteriology*, vol. 181, no. 13, pp. 4098–4102, 1999.
- [50] W.-K. Huh and S.-O. Kang, "Characterization of the gene family encoding alternative oxidase from *Candida albicans*," *Biochemical Journal*, vol. 356, no. 2, pp. 595–604, 2001.
- [51] F. Ruy, A. E. Vercesi, and A. J. Kowaltowski, "Inhibition of specific electron transport pathways leads to oxidative stress and decreased *Candida albicans* proliferation," *Journal of Bioenergetics and Biomembranes*, vol. 38, no. 2, pp. 129–135, 2006.
- [52] H. Tripathi, S. Luqman, A. Meena, and F. Khan, "Genomic identification of potential targets unique to *Candida albicans* for the discovery of antifungal agents," *Current Drug Targets*, vol. 15, no. 1, pp. 136–149, 2014.
- [53] S. Takahata, N. Kubota, N. Takei-Masuda et al., "Mechanism of action of ME1111, a novel antifungal agent for topical treatment of onychomycosis," *Antimicrobial Agents and Chemotherapy*, vol. 60, no. 2, pp. 873–880, 2016.
- [54] H. Mahmoudvand, S. A. Ayatollahi Mousavi, A. Sepahvand et al., "Antifungal, antileishmanial, and cytotoxicity activities of various extracts of *berberis vulgaris* (berberidaceae) and its active principle berberine," *ISRN Pharmacology*, vol. 2014, Article ID 602436, 6 pages, 2014.
- [55] Y. Xu, Y. Wang, L. Yan et al., "Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant *Candida albicans*: endogenous ROS augmentation," *Journal of Proteome Research*, vol. 8, no. 11, pp. 5296–5304, 2009.
- [56] D.-D. Li, Y. Xu, D.-Z. Zhang et al., "Fluconazole assists berberine to kill fluconazole-resistant *Candida albicans*," *Antimicrobial Agents and Chemotherapy*, vol. 57, no. 12, pp. 6016–6027, 2013.
- [57] S. Dhamgaye, F. Devaux, P. Vandeputte et al., "Molecular mechanisms of action of herbal antifungal alkaloid berberine, in *Candida Albicans*," *PLoS ONE*, vol. 9, no. 8, Article ID e104554, 2014.
- [58] S.-L. Zhu, L. Yan, Y.-X. Zhang et al., "Berberine inhibits fluphenazine-induced up-regulation of CDRI in *Candida albicans*," *Biological & Pharmaceutical Bulletin*, vol. 37, no. 2, pp. 268–273, 2014.
- [59] S. Okubo, T. Uto, A. Goto et al., "Berberine induces apoptotic cell death via activation of caspase-3 and -8 in HL-60 human leukemia cells: nuclear localization and structure–activity relationships," *American Journal of Chinese Medicine*, vol. 45, no. 07, pp. 1497–1511, 2017.
- [60] L. Li, X. Wang, R. Sharvan, J. Gao, and S. Qu, "Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways," *Biomedicine & Pharmacotherapy*, vol. 95, pp. 1225–1231, 2017.
- [61] J. S. Teodoro, F. V. Duarte, A. P. Gomes et al., "Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation," *Mitochondrion*, vol. 13, no. 6, pp. 637–646, 2013.
- [62] Y. Sun, X. Yuan, F. Zhang et al., "Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells," *Scientific Reports*, vol. 7, no. 1, article 11340, 2017.
- [63] S. Lee, E. Moon, S. U. Choi, and K. H. Kim, "Lignans from the Twigs of *Euonymus alatus* (Thunb.) Siebold and their biological evaluation," *Chemistry & Biodiversity*, vol. 13, pp. 1391–1396, 2016.
- [64] Y. Lin, A. Wolk, N. Håkansson, J. Lagergren, and Y. Lu, "Dietary intake of lignans and risk of esophageal and gastric adenocarcinoma: a cohort study in Sweden," *Cancer Epidemiology, Biomarkers & Prevention*, vol. 22, no. 2, pp. 308–312, 2013.
- [65] L. Meija, P. Söderholm, A. Samaletdin et al., "Dietary intake and major sources of plant lignans in Latvian men and women," *International Journal of Food Sciences and Nutrition*, vol. 64, no. 5, pp. 535–543, 2013.
- [66] K. M. Lemar, O. Passa, M. A. Aon et al., "Allyl alcohol and garlic (*Allium sativum*) extract produce oxidative stress in *Candida albicans*," *Microbiology*, vol. 151, no. 10, pp. 3257–3265, 2005.
- [67] L. M. Kaminskas, S. M. Pyke, and P. C. Burcham, "Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice," *The Journal of Pharmacology and Experimental Therapeutics*, vol. 310, no. 3, pp. 1003–1010, 2004.
- [68] S. Yang, Y. Fu, X. Wu et al., "Baicalin prevents *Candida albicans* infections via increasing its apoptosis rate," *Biochemical and Biophysical Research Communications*, vol. 451, no. 1, pp. 36–41, 2014.
- [69] T. K. Ha, A. H. Hansen, S. Kol, H. F. Kildegaard, and G. M. Lee, "Baicalein reduces oxidative stress in CHO cell cultures and improves recombinant antibody productivity," *Biotechnology Journal*, 2017.
- [70] L. Zhang, X. Wang, R. Wang et al., "Baicalin potentiates TRAIL-induced apoptosis through p38 MAPK activation and intracellular reactive oxygen species production," *Molecular Medicine Reports*, vol. 16, pp. 8549–8555, 2017.
- [71] D. Wan and H. Ouyang, "Baicalin induces apoptosis in human osteosarcoma cell through ROS-mediated mitochondrial pathway," *Natural Product Research*, pp. 1–5, 2017.
- [72] V. Y. Waisundara, A. Hsu, B. K. Tan, and D. Huang, "Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats," *Diabetes/Metabolism Research and Reviews*, vol. 25, no. 7, pp. 671–677, 2009.

- [73] S.-J. Kim, Y.-J. Moon, and S.-M. Lee, "Protective effects of baicalin against ischemia/reperfusion injury in rat liver," *Journal of Natural Products*, vol. 73, no. 12, pp. 2003–2008, 2010.
- [74] H. Miao, L. Zhao, C. Li et al., "Inhibitory effect of Shikonin on *Candida albicans* growth," *Biological & Pharmaceutical Bulletin*, vol. 35, no. 11, pp. 1956–1963, 2012.
- [75] X. Tang, C. Zhang, J. Wei, Y. Fang, R. Zhao, and J. Yu, "Apoptosis is induced by shikonin through the mitochondrial signaling pathway," *Molecular Medicine Reports*, vol. 13, no. 4, pp. 3668–3674, 2016.
- [76] W. Liang, A. Cai, G. Chen et al., "Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species," *Scientific Reports*, vol. 6, Article ID 38267, 2016.
- [77] N. Khan, S. Shreaz, R. Bhatia et al., "Anticandidal activity of curcumin and methyl cinnamaldehyde," *Fitoterapia*, vol. 83, no. 3, pp. 434–440, 2012.
- [78] M. Sharma, R. Manoharlal, A. S. Negi, and R. Prasad, "Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis," *FEMS Yeast Research*, vol. 10, no. 5, pp. 570–578, 2010.
- [79] M. Sharma, R. Manoharlal, N. Puri, and R. Prasad, "Antifungal curcumin induces reactive oxygen species and triggers an early apoptosis but prevents hyphae development by targeting the global repressor TUP1 in *Candida albicans*," *Bioscience Reports*, vol. 30, no. 6, pp. 391–404, 2010.
- [80] J. Trujillo, L. F. Granados-Castro, C. Zazueta, A. C. Andérica-Romero, Y. I. Chirino, and J. Pedraza-Chaverri, "Mitochondria as a target in the therapeutic properties of curcumin," *Archiv der Pharmazie*, vol. 347, no. 12, pp. 873–884, 2014.
- [81] S. Mou, Z. Zhou, Y. He, F. Liu, and L. Gong, "Curcumin inhibits cell proliferation and promotes apoptosis of laryngeal cancer cells through Bcl-2 and PI3K/Akt, and by upregulating miR-15a," *Oncology Letters*, vol. 14, pp. 4937–4942, 2017.
- [82] C. D. Lao, M. T. Ruffin IV, D. Normolle et al., "Dose escalation of a curcuminoid formulation," *BMC Complementary and Alternative Medicine*, vol. 6, article 10, 2006.
- [83] R. Salmazi, G. Calixto, J. Bernegossi et al., "A Curcumin-loaded liquid crystal precursor mucoadhesive system for the treatment of vaginal candidiasis," *International Journal of Nanomedicine*, vol. 10, pp. 4815–4824, 2015.
- [84] D. G. Yun and D. G. Lee, "Silibinin triggers yeast apoptosis related to mitochondrial Ca²⁺ influx in *Candida albicans*," *The International Journal of Biochemistry & Cell Biology*, vol. 80, pp. 1–9, 2016.
- [85] J. Schümann, J. Prockl, A. K. Kiemer, A. M. Vollmar, R. Bang, and G. Tiegs, "Silibinin protects mice from T cell-dependent liver injury," *Journal of Hepatology*, vol. 39, no. 3, pp. 333–340, 2003.
- [86] Y. Li, Z. Ye, W. Lai et al., "Activation of sirtuin 3 by silibinin attenuates mitochondrial dysfunction in cisplatin-induced acute kidney injury," *Frontiers in Pharmacology*, vol. 8, no. 178, 2017.
- [87] J. Ham, W. Lim, F. W. Bazer, and G. Song, "Silibinin stimulates apoptosis by inducing generation of ROS and ER stress in human choriocarcinoma cells," *Journal of Cellular Physiology*, vol. 233, no. 2, pp. 1638–1649, 2018.
- [88] M. Lazzeroni, A. Guerrieri-Gonzaga, S. Gandini et al., "A presurgical study of oral silibinin-phosphatidylcholine in patients with early breast cancer," *Cancer Prevention Research*, vol. 9, no. 1, pp. 89–95, 2016.
- [89] A. J. P. Brown, F. C. Odds, and N. A. R. Gow, "Infection-related gene expression in *Candida albicans*," *Current Opinion in Microbiology*, vol. 10, no. 4, pp. 307–313, 2007.
- [90] C. A. Kumamoto and M. D. Vines, "Contributions of hyphae and hypha-co-regulated genes to *Candida albicans* virulence," *Cellular Microbiology*, vol. 7, no. 11, pp. 1546–1554, 2005.
- [91] Z. Rashki Ghalehnoo, A. Rashki, M. Najimi, and A. Dominguez, "The role of diclofenac sodium in the dimorphic transition in *Candida albicans*," *Microbial Pathogenesis*, vol. 48, no. 3–4, pp. 110–115, 2010.
- [92] L. De Sordi and F. A. Mühlischlegel, "Quorum sensing and fungal-bacterial interactions in *Candida albicans*: a communicative network regulating microbial coexistence and virulence," *FEMS Yeast Research*, vol. 9, no. 7, pp. 990–999, 2009.
- [93] A. S. Gilbert, R. T. Wheeler, and R. C. May, "Fungal pathogens: survival and replication within macrophages," *Cold Spring Harbor Perspectives in Medicine*, vol. 5, no. 7, article a019661, 2015.
- [94] J. M. Bain, L. E. Lewis, B. Okai, J. Quinn, N. A. R. Gow, and L.-P. Erwig, "Non-lytic expulsion/exocytosis of *Candida albicans* from macrophages," *Fungal Genetics and Biology*, vol. 49, no. 9, pp. 677–678, 2012.
- [95] N. Uwamahoro, J. Verma-Gaur, H.-H. Shen et al., "The pathogen *Candida albicans* hijacks pyroptosis for escape from macrophages," *mBio*, vol. 5, no. 2, pp. e00003–e00014, 2014.
- [96] M. Wellington, K. Koselny, F. S. Sutterwala, and D. J. Krysan, "*Candida albicans* triggers NLRP3-mediated pyroptosis in macrophages," *Eukaryotic Cell*, vol. 13, no. 2, pp. 329–340, 2014.
- [97] M. Wellington, K. Koselny, and D. J. Krysan, "*Candida albicans* morphogenesis is not required for macrophage interleukin 1 β production," *mBio*, vol. 4, no. 1, pp. e00433–00412, 2012.
- [98] D. L. Moyes, D. Wilson, J. P. Richardson et al., "Candidalysin is a fungal peptide toxin critical for mucosal infection," *Nature*, vol. 532, no. 7597, pp. 64–68, 2016.
- [99] A. M. A. El-Asrar, L. Missotten, and K. Geboes, "Expression of hypoxia-inducible factor-1 α and the protein products of its target genes in diabetic fibrovascular epiretinal membranes," *British Journal of Ophthalmology*, vol. 91, no. 6, pp. 822–826, 2007.
- [100] P. A. de Castro, V. L. P. Bom, N. A. Brown et al., "Identification of the cell targets important for propolis-induced cell death in *Candida albicans*," *Fungal Genetics and Biology*, vol. 60, pp. 74–86, 2013.
- [101] J. Shareck, A. Nantel, and P. Belhumeur, "Conjugated linoleic acid inhibits hyphal growth in *Candida albicans* by modulating Ras1p cellular levels and downregulating TEC1 expression," *Eukaryotic Cell*, vol. 10, no. 4, pp. 565–577, 2011.
- [102] L. Sun, K. Liao, and D. Wang, "Effects of magnolol and honokiol on adhesion, yeast-hyphal transition, and formation of biofilm by *Candida albicans*," *PLoS ONE*, vol. 10, no. 2, Article ID e0117695, 2015.
- [103] D. Seleem, B. Benso, J. Noguti, V. Pardi, and R. M. Murata, "In vitro and in vivo antifungal activity of licochalcone-A against *Candida albicans* biofilms," *PLoS ONE*, vol. 11, no. 6, Article ID e0157188, 2016.
- [104] P. W.-K. Tsang, H. M. H. N. Bandara, and W.-P. Fong, "Purpurin suppresses *Candida albicans* Biofilm formation and hyphal development," *PLoS ONE*, vol. 7, no. 11, Article ID e50866, 2012.
- [105] C. Messier and D. Grenier, "Effect of licorice compounds licochalcone A, glabridin and glycyrrhizic acid on growth and virulence properties of *Candida albicans*," *Mycoses*, vol. 54, no. 6, pp. e801–e806, 2011.

- [106] N. Robbins, P. Uppuluri, J. Nett et al., "Hsp90 governs dispersion and drug resistance of fungal biofilms," *PLoS Pathogens*, vol. 7, no. 9, Article ID e1002257, 2011.
- [107] M. Feldman, A. Al-Quntar, I. Polacheck, M. Friedman, and D. Steinberg, "Therapeutic potential of thiazolidinedione-8 as an antibiofilm agent against *Candida albicans*," *PLoS ONE*, vol. 9, no. 5, Article ID e93225, 2014.
- [108] G. Ramage, S. N. Robertson, and C. Williams, "Strength in numbers: antifungal strategies against fungal biofilms," *International Journal of Antimicrobial Agents*, vol. 43, no. 2, pp. 114–120, 2014.
- [109] S. Fanning and A. P. Mitchell, "Fungal biofilms," *PLoS Pathogens*, vol. 8, no. 4, p. e1002585, 2012.
- [110] G. L. Semenza, "Regulation of mammalian O₂ homeostasis by hypoxia-inducible factor 1," *Annual Review of Cell and Developmental Biology*, vol. 15, pp. 551–578, 1999.
- [111] P. Uppuluri, J. Nett, J. Heitman, and D. Andes, "Synergistic effect of calcineurin inhibitors and fluconazole against *Candida albicans* biofilms," *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 3, pp. 1127–1132, 2008.
- [112] J. V. Desai, A. P. Mitchell, and D. R. Andes, "Fungal biofilms, drug resistance, and recurrent infection," *Cold Spring Harbor Perspectives in Medicine*, vol. 4, no. 10, 2014.
- [113] T. Bjarnsholt, O. Ciofu, S. Molin, M. Givskov, and N. Høiby, "Applying insights from biofilm biology to drug development—can a new approach be developed?" *Nature Reviews Drug Discovery*, vol. 12, no. 10, pp. 791–808, 2013.
- [114] R. H. Pires, L. B. Montanari, C. H. G. Martins et al., "Anticandidal efficacy of cinnamon oil against planktonic and biofilm cultures of *Candida parapsilosis* and *Candida orthopsilosis*," *Mycopathologia*, vol. 172, no. 6, pp. 453–464, 2011.
- [115] M. S. A. Khan and I. Ahmad, "Antibiofilm activity of certain phytochemicals and their synergy with fluconazole against *Candida albicans* biofilms," *Journal of Antimicrobial Chemotherapy*, vol. 67, no. 3, pp. 618–621, 2012.
- [116] D. Kocevski, M. Du, J. Kan, C. Jing, I. Lačanin, and H. Pavlović, "Antifungal effect of *Allium tuberosum*, *Cinnamomum cassia*, and *Pogostemon cablin* essential oils and their components against population of *Aspergillus* species," *Journal of Food Science*, vol. 78, no. 5, pp. M731–M737, 2013.
- [117] G.-X. Wei, X. Xu, and C. D. Wu, "In vitro synergism between berberine and miconazole against planktonic and biofilm *Candida* cultures," *Archives of Oral Biology*, vol. 56, no. 6, pp. 565–572, 2011.
- [118] M. Shahzad, L. Sherry, R. Rajendran, C. A. Edwards, E. Combet, and G. Ramage, "Utilising polyphenols for the clinical management of *Candida albicans* biofilms," *International Journal of Antimicrobial Agents*, vol. 44, no. 3, pp. 269–273, 2014.
- [119] A. Rašković, N. Pavlović, M. Kvrđić et al., "Effects of pharmaceutical formulations containing thyme on carbon tetrachloride-induced liver injury in rats," *BMC Complementary and Alternative Medicine*, vol. 15, no. 1, article no. 442, 2015.
- [120] L. He, H. Mo, S. Hadisusilo, A. A. Qureshi, and C. E. Elson, "Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo," *Journal of Nutrition*, vol. 127, no. 5, pp. 668–674, 1997.
- [121] N. Guo, J. Liu, X. Wu et al., "Antifungal activity of thymol against clinical isolates of fluconazole-sensitive and -resistant *Candida albicans*," *Journal of Medical Microbiology*, vol. 58, no. 8, pp. 1074–1079, 2009.
- [122] C. Shu, L. Sun, and W. Zhang, "Thymol has antifungal activity against *Candida albicans* during infection and maintains the innate immune response required for function of the p38 MAPK signaling pathway in *Caenorhabditis elegans*," *Immunologic Research*, vol. 64, no. 4, pp. 1013–1024, 2016.
- [123] S. C. Pemmaraju, P. A. Pruthi, R. Prasad, and V. Pruthi, "Candida albicans biofilm inhibition by synergistic action of terpenes and fluconazole," *Indian Journal of Experimental Biology (IJEB)*, vol. 51, no. 11, pp. 1032–1037, 2013.
- [124] K. P. Shirley, L. J. Windsor, G. J. Eckert, and R. L. Gregory, "In vitro effects of *Plantago major* extract, aucubin, and baicalein on *Candida albicans* biofilm formation, metabolic activity, and cell surface hydrophobicity," *Journal of Prosthodontics*, vol. 26, no. 6, pp. 508–515, 2017.
- [125] H. Carrasco, M. Raimondi, L. Svetaz et al., "Antifungal activity of eugenol analogues. Influence of different substituents and studies on mechanism of action," *Molecules*, vol. 17, no. 1, pp. 1002–1024, 2012.
- [126] A. Ahmad, A. Khan, L. A. Khan, and N. Manzoor, "In vitro synergy of eugenol and methyleugenol with fluconazole against clinical *Candida* isolates," *Journal of Medical Microbiology*, vol. 59, no. 10, pp. 1178–1184, 2010.
- [127] M. J. Saharkhiz, M. Motamedi, K. Zomorodian, K. Pakshir, R. Miri, and K. Hemyari, "Chemical composition, antifungal and antibiofilm activities of the essential oil of *Mentha piperita* L," *ISRN Pharmaceutics*, vol. 2012, Article ID 718645, 6 pages, 2012.
- [128] F. Solórzano-Santos and M. G. Miranda-Novales, "Essential oils from aromatic herbs as antimicrobial agents," *Current Opinion in Biotechnology*, vol. 23, no. 2, pp. 136–141, 2012.
- [129] C. M. C. Souza, S. A. Pereira Junior, T. da Silva Moraes, J.L. Damasceno, S. Amorim Mendes, H.J. Dias et al., "Antifungal activity of plant-derived essential oils on *Candida tropicalis* planktonic and biofilms cells," *Medical Mycology*, vol. 54, no. 5, pp. 515–523, 2016.
- [130] S. K. Doke, J. S. Raut, S. Dhawale, and S. M. Karuppaiyil, "Sensitization of *Candida albicans* biofilms to fluconazole by terpenoids of plant origin," *The Journal of General and Applied Microbiology*, vol. 60, no. 5, pp. 163–168, 2014.
- [131] K. Ingólfssdóttir, "Usnic acid," *Phytochemistry*, vol. 61, no. 7, pp. 729–736, 2002.
- [132] P. Nithyanand, R. M. Beema Shafreen, S. Muthamil, and S. Karutha Pandian, "Usnic acid inhibits biofilm formation and virulent morphological traits of *Candida albicans*," *Microbiological Research*, vol. 179, pp. 20–28, 2015.
- [133] R. H. Pires, R. Lucarini, and M. J. S. Mendes-Giannini, "Effect of usnic acid on *Candida orthopsilosis* and *C. parapsilosis*," *Antimicrobial Agents and Chemotherapy*, vol. 56, no. 1, pp. 595–597, 2012.
- [134] A. R. Da Silva, J. B. De Andrade Neto, C. R. Da Silva et al., "Berberine antifungal activity in fluconazole-resistant pathogenic yeasts: action mechanism evaluated by flow cytometry and biofilm growth inhibition in *Candida* spp," *Antimicrobial Agents and Chemotherapy*, vol. 60, no. 6, pp. 3551–3557, 2016.
- [135] M. Janeczko, M. Masłyk, K. Kubiński, and H. Golczyk, "Emodin, a natural inhibitor of protein kinase CK2, suppresses growth, hyphal development, and biofilm formation of *Candida albicans*," *Yeast*, vol. 34, no. 6, pp. 253–265, 2017.
- [136] M. C. Lorenz and G. R. Fink, "The glyoxylate cycle is required for fungal virulence," *Nature*, vol. 412, no. 6842, pp. 83–86, 2001.
- [137] F. G. Costa, B. R. Da Silva Neto, R. L. Gonçalves et al., "Alkaloids as inhibitors of malate synthase from paracoccidioides spp.: Receptor-ligand interaction-based virtual screening and

- molecular docking studies, antifungal activity, and the adhesion process,” *Antimicrobial Agents and Chemotherapy*, vol. 59, no. 9, pp. 5581–5594, 2015.
- [138] H.-L. Cheah, V. Lim, and D. Sandai, “Inhibitors of the glyoxylate cycle enzyme ICL1 in *Candida albicans* for potential use as antifungal agents,” *PLoS ONE*, vol. 9, no. 4, Article ID e95951, 2014.
- [139] J. Madunić, I. V. Madunić, G. Gajski, J. Popić, and V. Garaj-Vrhovac, “Apigenin: a dietary flavonoid with diverse anticancer properties,” *Cancer Letters*, vol. 413, pp. 11–22, 2018.
- [140] A. Corral-Lugo, A. Daddaoua, A. Ortega, M. Espinosa-Urgel, and T. Krell, “Rosmarinic acid is a homoserine lactone mimic produced by plants that activates a bacterial quorum-sensing regulator,” *Science Signaling*, vol. 9, no. 409, article no. ra1, 2016.
- [141] M. A. Ansari, Z. Fatima, K. Ahmad, and S. Hameed, “Monoterpeneoid perillyl alcohol impairs metabolic flexibility of *Candida albicans* by inhibiting glyoxylate cycle,” *Biochemical and Biophysical Research Communications*, 2017.
- [142] L. Duelund, A. Amiot, A. Fillon, and O. G. Mouritsen, “Influence of the active compounds of *Perilla frutescens* leaves on lipid membranes,” *Journal of Natural Products*, vol. 75, no. 2, pp. 160–166, 2012.
- [143] J. Ma, J. Li, K. S. Wang et al., “Perillyl alcohol efficiently scavenges activity of cellular ROS and inhibits the translational expression of hypoxia-inducible factor-1 α via mTOR/4E-BP1 signaling pathways,” *International Immunopharmacology*, vol. 39, pp. 1–9, 2016.
- [144] G. Liu, K. Oettel, H. Bailey et al., “Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer,” *Investigational New Drugs*, vol. 21, no. 3, pp. 367–372, 2003.
- [145] J. E. Nett, R. Zarnowski, J. Cabezas-Olcoz et al., “Host contributions to construction of three device-associated *Candida albicans* biofilms,” *Infection and Immunity*, vol. 83, no. 12, pp. 4630–4638, 2015.
- [146] B. N. Singh, D. K. Upreti, B. R. Singh et al., “Quercetin sensitizes fluconazole-resistant *Candida albicans* to induce apoptotic cell death by modulating quorum sensing,” *Antimicrobial Agents and Chemotherapy*, vol. 59, no. 4, pp. 2153–2168, 2015.
- [147] A. Davis-Hanna, A. E. Piispanen, L. I. Stateva, and D. A. Hogan, “Farnesol and dodecanol effects on the *Candida albicans* Ras1-cAMP signalling pathway and the regulation of morphogenesis,” *Molecular Microbiology*, vol. 67, no. 1, pp. 47–62, 2008.
- [148] C. J. Nobile, J. E. Nett, A. D. Hernday et al., “Biofilm matrix regulation by *Candida albicans* Zap1,” *PLoS Biology*, vol. 7, no. 6, Article ID e1000133, 2009.
- [149] A. Deveau and D. A. Hogan, “Linking quorum sensing regulation and biofilm formation by *Candida albicans*,” *Methods in Molecular Biology*, vol. 692, pp. 219–233, 2011.
- [150] M. A. S. Alem, M. D. Y. Oteef, T. H. Flowers, and L. J. Douglas, “Production of tyrosol by *Candida albicans* biofilms and its role in quorum sensing and biofilm development,” *Eukaryotic Cell*, vol. 5, no. 10, pp. 1770–1779, 2006.
- [151] L. S. Arias, A. C. B. Delbem, R. A. Fernandes, D. B. Barbosa, and D. R. Monteiro, “Activity of tyrosol against single and mixed-species oral biofilms,” *Journal of Applied Microbiology*, vol. 120, no. 5, pp. 1240–1249, 2016.
- [152] M. Yordanov, P. Dimitrova, S. Patkar, L. Saso, and N. Ivanovska, “Inhibition of *Candida albicans* extracellular enzyme activity by selected natural substances and their application in *Candida* infection,” *Canadian Journal of Microbiology*, vol. 54, no. 6, pp. 435–440, 2008.
- [153] M. Gao, H. Wang, and L. Zhu, “Quercetin assists fluconazole to inhibit biofilm formations of fluconazole-resistant *Candida albicans* in in vitro and in vivo antifungal managements of vulvovaginal candidiasis,” *Cellular Physiology and Biochemistry*, vol. 40, no. 3–4, pp. 727–742, 2016.
- [154] M. Girardot and C. Imbert, “Novel strategies against *Candida* biofilms: interest of synthetic compounds,” *Future Microbiology*, vol. 11, no. 1, pp. 69–79, 2016.
- [155] H. H. Lara, D. G. Romero-Urbina, C. Pierce, J. L. Lopez-Ribot, M. J. Arellano-Jiménez, and M. Jose-Yacamán, “Effect of silver nanoparticles on *Candida albicans* biofilms: an ultrastructural study,” *Journal of Nanobiotechnology*, vol. 13, no. 1, article no. 91, 2015.
- [156] L.-X. Ren, Y.-F. Luo, X. Li, D.-Y. Zuo, and Y.-L. Wu, “Antidepressant-like effects of sarsasapogenin from *Anemarrhena asphodeloides* Bunge (Liliaceae),” *Biological & Pharmaceutical Bulletin*, vol. 29, no. 11, pp. 2304–2306, 2006.
- [157] Y. Iida, K.-B. Oh, M. Saito, H. Matsuoka, and H. Kurata, “In vitro synergism between nyasol, an active compound isolated from *Anemarrhena asphodeloides*, and azole agents against *Candida albicans*,” *Planta Medica*, vol. 66, no. 5, pp. 435–438, 2000.
- [158] H. J. Park, J. Y. Lee, S. S. Moon, and B. K. Hwang, “Isolation and anti-oomycete activity of nyasol from *Anemarrhena asphodeloides* rhizomes,” *Phytochemistry*, vol. 64, no. 5, pp. 997–1001, 2003.
- [159] Y. Iida, K.-B. Oh, M. Saito et al., “Detection of antifungal activity in *Anemarrhena asphodeloides* by sensitive BCT method and isolation of its active compound,” *Journal of Agricultural and Food Chemistry*, vol. 47, no. 2, pp. 584–587, 1999.
- [160] M. N. Gallucci, M. E. Carezzano, M. M. Oliva et al., “In vitro activity of natural phenolic compounds against fluconazole-resistant *Candida* species: a quantitative structure-activity relationship analysis,” *Journal of Applied Microbiology*, vol. 116, no. 4, pp. 795–804, 2014.
- [161] R. X. Tan, H. Q. Tang, J. Hu, and B. Shuai, “Lignans and sesquiterpene lactones from *Artemisia sieversiana* and *Inula racemosa*,” *Phytochemistry*, vol. 49, no. 1, pp. 157–161, 1998.
- [162] J. Wildenhain, M. Spitzer, S. Dolma et al., “Prediction of synergism from chemical-genetic interactions by machine learning,” *Cell Systems*, vol. 1, no. 6, pp. 383–395, 2015.
- [163] M. Spitzer, N. Robbins, and G. D. Wright, “Combinatorial strategies for combating invasive fungal infections,” *Virulence*, vol. 8, no. 2, pp. 169–185, 2017.
- [164] G. D. Wright, “Antibiotic adjuvants: rescuing antibiotics from resistance,” *Trends in Microbiology*, vol. 24, no. 11, pp. 862–871, 2016.
- [165] A. M. Wassermann, E. Lounkine, D. Hoepfner et al., “Dark chemical matter as a promising starting point for drug lead discovery,” *Nature Chemical Biology*, vol. 11, no. 12, pp. 958–966, 2015.



Hindawi

Submit your manuscripts at
<https://www.hindawi.com>

